European advisory group backs Roche’s Tecentriq in first-line liver cancer

The European Medicines Agency’s advisory group CHMP has adopted a positive opinion backing the use of Roche’s (OTCQX:RHHBY +1.4%) Tecentriq (atezolizumab), combined with Avastin (bevacizumab), for the treatment of adults with advanced or unresectable hepatocellular carcinoma in a first-line setting.

The PD-L1 inhibitor is currently approved in Europe for the treatment of urothelial, non-small cell lung, small cell lung and breast cancers.

A final decision from the European Commission usually takes ~60 days.

https://seekingalpha.com/news/3615348-european-advisory-group-backs-roches-tecentriq-in-first-line-liver-cancer